Bromelain’s penetration into the blood and sinonasal mucosa in patients with chronic rhinosinusitis
The aim of this research is to investigate penetration of Bromelain into sinonasal mucosa in patients with chronic rhinosinusitis (CRS) versus a control group. Bromelain is derived from pineapple (Ananas comosus) and has various pharmacological effects. 40 patients (20 patients and 20 controls) were enrolled in the study. Bromelain 500 mg tablet twice daily was administered for 30 days. We scored bro- melain presence in turbinate and ethmoid mucosas and in the serum of both the groups. Bromelain has an excellent distribution from blood to rhinosinusal mucosa. Its diffusion ability may allow the use of bromelain as an anti-inflammatory agent in paranasal sinus pathologies.
We studied the penetration of bromelain into sinonasal mucosa in patients with CRS (group A) versus a control group (group B). Bromelain is derived from pineapple (Ananas comosus) and is a mixture of different substances, above all, proteolytic enzymes 1. It is used in therapy for many problems and has various pharmacological effects, but its mechanism of action is still not completely clear. Several studies, carried out to determine its activity and effectiveness, have identified antithrombin, anti-oedema and fibrinolytic activity.
Clinical trials have shown that bromelain is useful for the therapy of several disorders such as chronic inflammation and autoimmune diseases 2, particularly osteoarthritis and rheumatoid arthritis 3-5. In vitro, it has demonstrated the ability to modulate the immune response to reduce the allergic reaction and to modulate macrophages, NK cells and T cells. It also increases the secretion of IL-1β, IL-6 and TNFα 6.
In vitro and in vivo research suggests that bromelain may interfere with pathogens such as Vibrio cholera and Escherichia coli, whose toxins cause diarrhoea 7.
Finally, in vitro studies highlight that bromelain has anti-tumoural activity, through an increase of concentration-dependent inhibition of cancer cell proliferation 10.
Materials and methods
We enrolled 20 patients (13 males, 7 females; 22-77 years) with CRS diagnosed according to the “International Consensus Statement on Allergy and Rhinology” 11 and EPOS criteria 12 13 as group A and 20 patients (9 males, 11 females; 26-64 years) without sinonasal problems as group B.
We defined CRS as rhinosinusal inflammation lasting for more than 12 weeks and characterised by nasal obstruction, nasal drip (anterior and/or posterior), facial pain and alteration of smell. These symptoms had to be associated with other findings including positive nasal endoscopy for presence of purulent secretions or positivity for sinus inflammation on CT scan. Sinus mucosal inflammation is staged, according to Lund-Mackay score system 14, as 0 (complete lucency), 1 (partial lucency) or 2 (complete opacity). The patients enrolled in group A belonged to Lund-Mackay Score grade 2.
This research was carried out with the ENT Dept. of Carol Davila University of Bucharest. All the patients had taken 1 tablet of bromelain 500 mg twice a day by mouth for 1 month.
All patients signed informed consent. The Bucharest Local Health Unit Ethics Committee approved our research. Guidelines and requirements of the Declaration of Helsinki have been respected.
Exclusion criteria were: any other concomitant systemic/topic drug treatment, presence of infections of other sites during all trials, hypersensitivity to any of the constituents of medication, pregnancy or lactation, hepatic or renal insufficiency 15.
For group A, ethmoid and middle turbinate mucosa were taken during functional endoscopic sinus surgery. For group B, samples were taken during transnasal pituitary surgery.
Immunohistochemistry analysis was carried on according to procedures present in the international literature, considered as the most valid and reliable 16.
Samples were washed for 30 seconds in 0.9% sodium chloride solution to minimise blood contamination, and then embedded in paraffin.
Paraffin sections were deparaffinised, rehydrated and rinsed in PBS, pH 7.4. Retrieval with cooking in specific buffer was raised in a microwave oven (Samsung) at 800 W for 5 minutes, and then 440 W for 10 minutes. The immunohistochemical method was an indirect two-stage technique performed with a polymer based detection system (Max Polymer Detection System–Leica RE 7280-k) according to the manufacturer’s instructions. All specimens were counterstained with Meyer’s haematoxylin, examined and photographed with a Nikon E 200 microscope. Tissue sections were tested by immunohistochemistry using monoclonal antibodies against bromelain (Agrisera AB/AS09 552). The dilution used was 1:2000, cooked overnight at 60° C, 3% H2O2.
We scored the quantity of bromelain present in samples of turbinate and ethmoid mucosa taken as grade 0, 1, 2, 3 and 4 based on the following: grade 0: no reaction; grade 1: positive reaction in #x003C; 25% of cells: grade 2: positive reaction in 25-50% of cells (Fig. 1); grade 3: positive reaction in 50-75% of cells (Fig. 2); grade 4: positive reaction > 75% of cells.
A blood sample was taken and bromelain in blood was determined using the Western-blotting method. We scored the presence of bromelain in serum in: 0: no Bromelain; 1: optical density (OD) values of the migration gel #x003C; 60,000; 2: OD values 60,000-80,000; 3: OD values 80,000-90,000; 4: OD values > 90,000.
The data collected are summarised in Table I. In Table I, for almost all enrolled subjects there was a good distribution of bromelain, from serum to nasal and sinus tissues. It is interesting to note that for 3 controls (group B), there was no distribution of bromelain either in serum or in rhinosinusal mucosa.
For patients, the distribution of bromelain between serum and turbinate tissue and between serum and ethmoid tissue was statistically significant (P value of both: 0.0004).
For control group, the P values were also significant (P value of bromelain distribution between serum and turbinate tissue: 0.0356; P value of Bromelain distribution between serum and ethmoid tissue: 0.0207). Results of immunohistochemistry are shown in Figures 1 and 2.
First of all, we can underline that the distribution of bromelain to serum and from serum to rhinosinusal tissues was higher in patients than in control.
Apart from the empirical results, there was important statistical significance, particularly for patients in group A. Thus, it can safely be stated that bromelain has an excellent distribution from serum to sino-nasal tissues, especially in patients with paranasal diseases. The results of controls (group B) were also statistically significant, even if this significance was less than in group A.
According to the International Rhinosinusitis Advisory Board 17, the goals of rhinosinusitis therapy are to treat the infection, shorten the disease and prevent recurrences; in order to achieve these goals, many different pharmacological approaches have been tested by several study groups. Acute rhinosinusitis (ARS) resolves without antibiotic treatment in most cases, symptomatic treatment and reassurance is the preferred initial management strategy for patients with mild symptoms. Antibiotic therapy should be reserved for patients with severe ARS, especially in presence of high fever or severe (unilateral) facial pain. Clinicians should weigh the moderate benefits of antibiotic treatment against the potential for adverse effects. The aim of a pharmacological approach in ARS is represented by the opening of the ostia, while in chronic inflammatory processes of the nose and paranasal sinuses the goal is to restore healthy respiratory mucosa.
As already stated, bromelain has well-known effects such as antithrombotic, anti-oedema and fibrinolytic activity, and it is active as anti-inflammatory drug in chronic inflammation and/or autoimmune diseases 3-5, reduction of allergic reaction, modulation of macrophages, NK cells and T cells and increase IL-1b, IL-6, and TNFa secretion 6. Considering these effects, the high concentration in CRS nasal cells we reported is good evidence of its strong potential in upper airways
These findings of the penetration of bromeline strongly call for confirmatory clinical trials in patients with CRS. In fact, the presence in tissue of a particular molecule, with known pharmacological effects, is the first step needed to continue with clinical studies.
Following our results, in the future it will be interesting to understand how distribution from serum to tissues is achieved, how it may be vary among patients and between patients and controls, and whether other modes of administration (for example intranasal administration) are equally effective or not.
Bromelain’s ability of diffusion as an anti-inflammatory drug could be exploited in the treatment of nasal and sinus pathologies. The pharmacokinetics and pharmacodynamics characteristics of Bromelain and its safety profile could make it an option to achieve therapeutic results in CRS, thanks to its good tolerability and safety with no specific restrictions.
Figures and tables
|Group A||Serum||Turbinate||Ethmoid||Group B||Serum||Turbinate||Ethmoid|
- Bhattacharyya BK. Bromelain: an overview. NPR. 2008; 7:359-63.
- Akhtar NM, Naseer R, Farooqi AZ. Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee-a double-blind prospective randomized study. Clin Rheumatol. 2004; 23:410-5.13.
- Mojcik CF, Shevach EM. Adhesion molecules: a rheumatologic perspective. Arthritis Rheum. 1997; 40:991-1004.
- Cohen A, Goldman J. Bromelain therapy in rheumatoid arthritis. Pennsyl Med J. 1964; 67:27-30.
- Leipner J, Iten F, Saller R. Therapy with proteolytic enzymes in rheumatic disorders. Bio Drugs. 2002; 15:779-89.
- Barth H, Guseo A, Klein R. In vitro study on the immunological effect of bromelain and trypsin on mononuclear cells from humans. Eur J Med Res. 2005; 10:325-31.
- Mynott TL, Guandalini S, Raimondi F. Bromelain prevents secretion caused by Vibrio cholerae and Escherichia coli enterotoxins in rabbit ileum in vitro. Gastroenterology. 1997; 113:175-84.
- Tassman GC, Zafran JN, Zayon GM. Evaluation of a plate proteolytic enzyme for the control of inflammation and pain. J Dent Med. 1964; 19:73-7.
- Tassman GC, Zafran JN, Zayon GM. A double-blind crossover study of a plant proteolytic enzyme in oral surgery. J Dent Med. 1965; 20:51-4.
- Orlandi RR, Kingdom TT, Hwang PH. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016; 6:S22-S209.
- Thomas M, Yawn BP, Price D. EPOS Primary Care Guidelines: European position paper on the primary care diagnosis and management of rhinosinusitis and nasal polyps 2007 - a summary. Prim Care Respir J. 2008; 17:79-89.
- Fokkens WJ1, Lund VJ, Mullol J. European Position Paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012; 23:3.
- Lund VJ, Mackay IS. Staging in rhinosinusitus. Rhinology. 1993; 31:183-4.
- De Benedetto M, Passali D, Tomacelli G. Penetration of prulifloxacin into sinus mucosa of patients undergoing paranasal sinus elective endoscopic surgery. J Chemother. 2012; 24:26-31.
- Georgescu A, Stoicea M, Comǎnescu M. Prognostic and predictive significance of the bcl-2/IgH translocation in malignant follicular lymphomas. Rom J Morphol Embryol. 2010; 51:687-91.
- International Rhinosinusitis Advisory Board. Infectious rhinosinusitis in adults: classification, etiology and management. Ear Nose Throat J. 1997; 76:1-22.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale , 2018
- Abstract viewed - 1531 times
- PDF downloaded - 679 times